Analysts Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $94.60

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) has been given a consensus rating of "Buy" by the five research firms that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $94.60.

APGE has been the subject of a number of recent research reports. Guggenheim reiterated a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Citigroup began coverage on shares of Apogee Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $95.00 price objective on the stock. Finally, Wedbush restated an "outperform" rating and set a $90.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, March 11th.

Insider Buying and Selling

In other news, CEO Michael Thomas Henderson sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total transaction of $301,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,292,987 shares of the company's stock, valued at approximately $38,983,558.05. This represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Carl Dambkowski sold 1,590 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.48, for a total value of $48,463.20. Following the completion of the sale, the insider now directly owns 251,033 shares in the company, valued at approximately $7,651,485.84. This trade represents a 0.63% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,175 shares of company stock worth $587,191 over the last ninety days. 42.77% of the stock is owned by insiders.

Institutional Trading of Apogee Therapeutics

A number of large investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Apogee Therapeutics by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company's stock worth $921,000 after purchasing an additional 694 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Apogee Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company's stock valued at $432,000 after purchasing an additional 892 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Apogee Therapeutics in the 4th quarter worth approximately $43,000. Arizona State Retirement System boosted its holdings in shares of Apogee Therapeutics by 17.3% in the fourth quarter. Arizona State Retirement System now owns 6,517 shares of the company's stock valued at $295,000 after acquiring an additional 960 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in shares of Apogee Therapeutics by 8.9% during the fourth quarter. New York State Common Retirement Fund now owns 12,187 shares of the company's stock valued at $552,000 after acquiring an additional 1,000 shares during the period. Institutional investors and hedge funds own 79.04% of the company's stock.

Apogee Therapeutics Stock Performance

NASDAQ APGE traded down $0.75 during trading hours on Thursday, hitting $38.73. 212,154 shares of the company's stock were exchanged, compared to its average volume of 523,441. The business's 50 day moving average is $36.72 and its 200-day moving average is $40.27. Apogee Therapeutics has a 12-month low of $26.20 and a 12-month high of $63.50. The firm has a market capitalization of $1.78 billion, a P/E ratio of -16.04 and a beta of 1.70.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.95) EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $0.24. As a group, equities research analysts anticipate that Apogee Therapeutics will post -3.09 EPS for the current fiscal year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.